Program
Tegafur
Also written as “S-1”, “S-1/Cisplatin” and “S-1, Irinotecan, Bevacizumab”.
Its studies are mostly in Stomach Neoplasms · Pancreatic Neoplasms · Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Renal Insufficiency, led by 4 companies.
Drug pageTegafur: every studyAll 189 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsukaits history only | 190 open or running | phase 3since Jun 30, 2005 | Jun 30, 2005 | none ahead |
| TTY Biopharmits history only | 40 open or running | phase 2since Mar 26, 2015 | Jun 4, 2013 | none ahead |
| Innovent Biologicsits history only | 11 open or running | phase 2since Mar 16, 2026 | Mar 16, 2026 | Jun 30, 2030phase 2 · NCT07483567 |
| Sanofi | 10 open or running | phase 3since Jan 16, 2008 | Jan 16, 2008 | none ahead |
Also a collaborator on its studies: Quintiles, United BioSource and Daiichi Sankyo.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sanofi only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 16, 2008First study: phase 3 study in Pancreatic NeoplasmsFirst studyNCT00602745 · 61 enrolled · United States, Austria, Brazil and more
TargetBeta
“RNA inhibitor; Thymidylate synthase inhibitor”ChEMBL 37, by rule
Other programs on TYMS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Pemetrexedrule | Eli Lilly | phase 4 | 141 |
| Capecitabinerule | Hoffmann-La Roche | phase 4 | 129 |
| Fluorouracilrule | Sanofi | phase 4 | 82 |
Studies
The one study Sanofi leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00602745Pancreatic Neoplasms · United States, Austria, Brazil and more | 3 | Terminated | Mar 2010 | 61 |
How it is read
Names in the registry
- “S-1”, 8 entries
- “S-1/Cisplatin”, 3 entries
- “S-1, Irinotecan, Bevacizumab”, 2 entries
- “IBI343,sintilimab,oxaliplatin,S-1”, 1 entry
- “S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm)”, 1 entry
Conditions, from the studies’ own filings
- Stomach Neoplasms, 5 studies
- Pancreatic Neoplasms, 5 studies
- Colorectal Neoplasms, 5 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.